To include your compound in the COVID-19 Resource Center, submit it here.

Campath alemtuzumab: Phase III data

In the open-label, international Phase III CAM307 trial in 297 treatment-naïve patients, Campath

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE